In total, 200 subjects were enrolled, and 197 participants
completed the present study. These individuals were
randomly assigned to fragmented CP1563 or control
treatments. The progress through the phases of the trial
is shown in Fig. 1. Three individuals discontinued participation
in the study because of an inability to comply with
the time constraint (n1) or an extended business trip
(n2). During the study, adverse effects, such as abnormal
values of hepatic or renal function, cutaneous symptoms,
nausea, abdominal discomfort, and edema caused by
PPARa or PPARg synthetic agonists, were not observed
in the test group. Although transient diarrhea (four
subjects in the placebo group and two subjects in the test
group) and constipation (two subjects in the placebo group
and one subject in the test group) were observed, the
doctor determined that the symptoms were not associated
with the intake of the supplementary beverages. No signs
of imbalance in the occurrence rates of unwellness between
the test and placebo groups were recorded.